Analysts Downgrade Ventyx Biosciences Target Price to $14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy VTYX?
Source: Benzinga
- Rating Downgrade: Canaccord Genuity analyst Edward Nash downgraded Ventyx Biosciences Inc (NASDAQ:VTYX) from Buy to Hold and lowered the price target from $16 to $14, reflecting a cautious outlook on the company's future growth potential.
- Market Reaction: Ventyx Biosciences shares closed at $13.73 on Wednesday, below the new target price, indicating investor concerns about the company's prospects, which may affect short-term capital inflows.
- Industry Impact: This rating change could prompt follow-up actions from other analysts, further influencing Ventyx's market performance, especially amid increasing competition in the biotech sector.
- Investor Confidence: The downgrade may undermine investor confidence in Ventyx, particularly as the company seeks to attract more investment to support its R&D and market expansion efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTYX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTYX
Wall Street analysts forecast VTYX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.38 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 13.940
Low
9.00
Averages
13.38
High
14.00
Current: 13.940
Low
9.00
Averages
13.38
High
14.00
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Proposed Sale of Ventyx Biosciences to Eli Lilly
- Acquisition Investigation: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti are investigating the proposed sale of Ventyx Biosciences to Eli Lilly, aiming to assess the fairness of the transaction.
- Shareholder Return Analysis: Under the proposal, Ventyx shareholders would receive $14.00 per share, yet the investigation seeks to determine if this price undervalues the company, potentially impacting shareholder interests.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for legal consultation, highlighting the firm's commitment to protecting shareholder rights.
- Company Background Information: Ventyx Biosciences is publicly traded on NASDAQ, and the potential implications of this transaction may spark extensive discussions regarding its future direction, particularly within the competitive landscape of the biotech sector.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE: STEL) regarding its sale to Prosperity Bancshares, Inc., which involves a price of 0.3803 shares of Prosperity common stock and $11.36 in cash per share of Stellar common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Implications: Upon completion of the merger between Community West Bancshares (NASDAQ: CWBC) and United Security Bancshares, Community West shareholders would own approximately 70.6% of the combined company, which could significantly impact shareholder rights and corporate governance structures.
- Acquisition Deal: SkyWater Technology, Inc. (NASDAQ: SKYT) is being sold for $15.00 in cash and $20.00 in IonQ common stock, with Halper Sadeh LLC potentially seeking increased compensation for shareholders, highlighting the importance of fair valuation in corporate transactions.
- Legal Support: Halper Sadeh LLC offers legal services on a contingency fee basis, encouraging shareholders to reach out to discuss their legal rights and options, demonstrating a commitment to protecting investor interests.
See More
Monteverde Law Firm Investigates Multiple Mergers and Acquisitions
- Skywater Technology Deal: Monteverde Law Firm is investigating the transaction between Skywater Technology and IonQ, where Skywater shareholders are expected to receive $15.00 per share in cash and $20.00 in IonQ common stock, potentially providing significant returns for shareholders.
- Community West Merger: In the merger between Community West Bancshares and United Security Bancshares, United Security shareholders are expected to receive 0.4520 shares of Community West common stock for each share they hold, indicating an increase in shareholder value through the merger.
- Stellar Bancorp Sale: In the transaction involving Stellar Bancorp and Prosperity Bancshares, Stellar shareholders are expected to receive 0.3803 shares of Prosperity common stock and $11.36 in cash per share, further enhancing the financial benefits for shareholders.
- Ventyx Biosciences Transaction: In the deal with Eli Lilly, Ventyx shareholders are expected to receive $14.00 in cash per share, with a shareholder vote scheduled for March 3, 2026, highlighting the urgency and potential profitability of the transaction.
See More
Investor Rights Investigation: Multiple Company Transactions
- Legal Investigation Launched: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE:STEL) for its sale to Prosperity Bancshares, Inc., which involves 0.3803 shares of Prosperity common stock and $11.36 in cash per share, potentially indicating breaches of fiduciary duties affecting shareholder rights.
- Shareholder Rights Protection: The transaction between Gold Resource Corporation (NYSE American: GORO) and Goldgroup Mining Inc. involves 1.4476 shares of Goldgroup common stock per share, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to safeguard shareholder interests.
- SkyWater Transaction Review: SkyWater Technology, Inc. (NASDAQ:SKYT) is involved in a sale to IonQ for $15.00 in cash and $20.00 in IonQ common stock, prompting Halper Sadeh LLC to assess whether this transaction aligns with shareholder best interests.
- Ventyx Transaction Investigation: Ventyx Biosciences, Inc. (NASDAQ:VTYX) is selling to Eli Lilly and Company for $14.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to discuss their legal rights and options to ensure their interests are protected.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE: STEL) regarding its sale to Prosperity Bancshares, Inc. for 0.3803 shares of Prosperity common stock and $11.36 in cash per share, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Scrutiny: The merger between Columbia Financial, Inc. (NASDAQ: CLBK) and Northfield Bancorp, Inc. is also under investigation, with Halper Sadeh LLC possibly seeking increased compensation and additional disclosures to protect shareholder interests.
- Shareholder Rights Protection: The sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is similarly scrutinized, with Halper Sadeh LLC encouraging shareholders to reach out to understand their legal rights and options.
- Legal Service Model: Halper Sadeh LLC operates on a contingent fee basis, allowing shareholders to seek legal remedies and potential compensation without upfront costs, demonstrating the firm's commitment to protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Protection: Monteverde Law Firm is investigating the transaction between Skywater Technology and IonQ, where Skywater shareholders are expected to receive $15.00 in cash and $20.00 in IonQ stock per share, aiming to ensure fair compensation for shareholders.
- Transaction Details: In the deal between Gold Resource Corporation and Goldgroup Mining, Gold Resource shareholders will convert their shares into 1.4476 common shares of Goldgroup, demonstrating a commitment to shareholder interests.
- Cash and Stock Combination: For the Stellar Bancorp and Prosperity Bancshares transaction, Stellar shareholders are expected to receive 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the company's strategy to reward shareholders.
- Upcoming Vote: In the transaction involving Ventyx Biosciences and Eli Lilly, Ventyx shareholders are expected to receive $14.00 in cash per share, with a shareholder vote scheduled for March 3, 2026, highlighting the importance of shareholder involvement in the transaction.
See More
Investigation into Proposed Sale of Ventyx Biosciences to Eli Lilly
- Acquisition Investigation: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti are investigating the proposed sale of Ventyx Biosciences to Eli Lilly, aiming to assess the fairness of the transaction.
- Shareholder Return Analysis: Under the proposal, Ventyx shareholders would receive $14.00 per share, yet the investigation seeks to determine if this price undervalues the company, potentially impacting shareholder interests.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for legal consultation, highlighting the firm's commitment to protecting shareholder rights.
- Company Background Information: Ventyx Biosciences is publicly traded on NASDAQ, and the potential implications of this transaction may spark extensive discussions regarding its future direction, particularly within the competitive landscape of the biotech sector.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE: STEL) regarding its sale to Prosperity Bancshares, Inc., which involves a price of 0.3803 shares of Prosperity common stock and $11.36 in cash per share of Stellar common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Implications: Upon completion of the merger between Community West Bancshares (NASDAQ: CWBC) and United Security Bancshares, Community West shareholders would own approximately 70.6% of the combined company, which could significantly impact shareholder rights and corporate governance structures.
- Acquisition Deal: SkyWater Technology, Inc. (NASDAQ: SKYT) is being sold for $15.00 in cash and $20.00 in IonQ common stock, with Halper Sadeh LLC potentially seeking increased compensation for shareholders, highlighting the importance of fair valuation in corporate transactions.
- Legal Support: Halper Sadeh LLC offers legal services on a contingency fee basis, encouraging shareholders to reach out to discuss their legal rights and options, demonstrating a commitment to protecting investor interests.
See More
Monteverde Law Firm Investigates Multiple Mergers and Acquisitions
- Skywater Technology Deal: Monteverde Law Firm is investigating the transaction between Skywater Technology and IonQ, where Skywater shareholders are expected to receive $15.00 per share in cash and $20.00 in IonQ common stock, potentially providing significant returns for shareholders.
- Community West Merger: In the merger between Community West Bancshares and United Security Bancshares, United Security shareholders are expected to receive 0.4520 shares of Community West common stock for each share they hold, indicating an increase in shareholder value through the merger.
- Stellar Bancorp Sale: In the transaction involving Stellar Bancorp and Prosperity Bancshares, Stellar shareholders are expected to receive 0.3803 shares of Prosperity common stock and $11.36 in cash per share, further enhancing the financial benefits for shareholders.
- Ventyx Biosciences Transaction: In the deal with Eli Lilly, Ventyx shareholders are expected to receive $14.00 in cash per share, with a shareholder vote scheduled for March 3, 2026, highlighting the urgency and potential profitability of the transaction.
See More
Investor Rights Investigation: Multiple Company Transactions
- Legal Investigation Launched: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE:STEL) for its sale to Prosperity Bancshares, Inc., which involves 0.3803 shares of Prosperity common stock and $11.36 in cash per share, potentially indicating breaches of fiduciary duties affecting shareholder rights.
- Shareholder Rights Protection: The transaction between Gold Resource Corporation (NYSE American: GORO) and Goldgroup Mining Inc. involves 1.4476 shares of Goldgroup common stock per share, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to safeguard shareholder interests.
- SkyWater Transaction Review: SkyWater Technology, Inc. (NASDAQ:SKYT) is involved in a sale to IonQ for $15.00 in cash and $20.00 in IonQ common stock, prompting Halper Sadeh LLC to assess whether this transaction aligns with shareholder best interests.
- Ventyx Transaction Investigation: Ventyx Biosciences, Inc. (NASDAQ:VTYX) is selling to Eli Lilly and Company for $14.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to discuss their legal rights and options to ensure their interests are protected.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Stellar Bancorp, Inc. (NYSE: STEL) regarding its sale to Prosperity Bancshares, Inc. for 0.3803 shares of Prosperity common stock and $11.36 in cash per share, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Scrutiny: The merger between Columbia Financial, Inc. (NASDAQ: CLBK) and Northfield Bancorp, Inc. is also under investigation, with Halper Sadeh LLC possibly seeking increased compensation and additional disclosures to protect shareholder interests.
- Shareholder Rights Protection: The sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is similarly scrutinized, with Halper Sadeh LLC encouraging shareholders to reach out to understand their legal rights and options.
- Legal Service Model: Halper Sadeh LLC operates on a contingent fee basis, allowing shareholders to seek legal remedies and potential compensation without upfront costs, demonstrating the firm's commitment to protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Protection: Monteverde Law Firm is investigating the transaction between Skywater Technology and IonQ, where Skywater shareholders are expected to receive $15.00 in cash and $20.00 in IonQ stock per share, aiming to ensure fair compensation for shareholders.
- Transaction Details: In the deal between Gold Resource Corporation and Goldgroup Mining, Gold Resource shareholders will convert their shares into 1.4476 common shares of Goldgroup, demonstrating a commitment to shareholder interests.
- Cash and Stock Combination: For the Stellar Bancorp and Prosperity Bancshares transaction, Stellar shareholders are expected to receive 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the company's strategy to reward shareholders.
- Upcoming Vote: In the transaction involving Ventyx Biosciences and Eli Lilly, Ventyx shareholders are expected to receive $14.00 in cash per share, with a shareholder vote scheduled for March 3, 2026, highlighting the importance of shareholder involvement in the transaction.
See More
